Nesiritide for Ventilated Congestive Heart Failure

Hemodynamic Effects of Nesiritide on Congestive Heart Failure Patients Receiving Mechanical Ventilation: A Prospective Observational Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04455477

Acronym

HENCHF

Enrollment

Registered

2020-07-02

Start date

2020-05-14

Completion date

2021-12-31

Last updated

2020-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Function, Congestive Heart Failure, Mechanical Ventilation, Using Nesiritide, Venous Return

Keywords

Congestive Heart Failure, Nesiritide

Brief summary

The congestive heart failure is a common disease among patients who receive cardiac surgery and may lead to prolonged ventilation support. Nesiritide was a potential therapy for congestive heart failure. This study aimed to compare the Nesiritide induced hemodynamical status changes among congestive heart failure patients with invasive ventilation support.

Interventions

DRUGNesiritide

The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age≥18 years； * Congestive Heart Failure; * With mechanical ventilation； * With hemodynamic monitoring devices; * The physicians made the decision of using Nesiritide.

Exclusion criteria

* Unstable hemodynamic status； * Severe renal dysfunction.

Design outcomes

Primary

Measure	Time frame	Description
Changes of cardiac output	Before and 30-min after using a standard dose of Nesiritide	Changes of cardiac output measured by hemodynamical monitoring tools
Changes of systemic filling pressure	Before and 30-min after using a standard dose of Nesiritide	Changes of the intercept of regression line of paired VR-RAP points at different PEEP levels.

Secondary

Measure	Time frame	Description
Changes of cardiac function curve	Before and 30-min after using a standard dose of Nesiritide	Using body position changes (±15°) to simulate the change of preload, and therefore depicte the Starling curve
Changes of venous return curve	Before and 30-min after using a standard dose of Nesiritide	Changes of venous return curve depicted by different PEEP setting

Countries

China

Contacts

Primary ContactZhe Luo, MD

luo.zhe@zs-hospital.sh.cn+8613916127028

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026